Wall Street brokerages expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report sales of $2.17 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $2.70 million and the lowest is $1.80 million. Xeris Pharmaceuticals reported sales of $310,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 600%. The firm is expected to report its next earnings report on Tuesday, August 4th.
According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current year, with estimates ranging from $12.30 million to $18.10 million. For the next fiscal year, analysts anticipate that the company will post sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The business had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $1.82 million.
NASDAQ XERS traded up $0.17 on Monday, hitting $2.68. The stock had a trading volume of 3,332,848 shares, compared to its average volume of 787,454. Xeris Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $12.94. The company has a debt-to-equity ratio of 2.16, a quick ratio of 4.72 and a current ratio of 4.82. The company has a market capitalization of $94.35 million, a price-to-earnings ratio of -0.56 and a beta of 2.10. The firm has a 50-day moving average of $4.64 and a 200-day moving average of $4.49.
In other news, insider John Patrick Shannon, Jr. purchased 22,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $3.55 per share, with a total value of $78,100.00. Following the acquisition, the insider now directly owns 117,493 shares in the company, valued at $417,100.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul R. Edick purchased 33,000 shares of the business’s stock in a transaction on Friday, May 8th. The stock was purchased at an average cost of $3.54 per share, for a total transaction of $116,820.00. Following the acquisition, the insider now owns 95,493 shares in the company, valued at $338,045.22. The disclosure for this purchase can be found here. 5.95% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Xeris Pharmaceuticals in the 1st quarter worth $26,000. Deutsche Bank AG grew its holdings in Xeris Pharmaceuticals by 40.7% in the 1st quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock worth $27,000 after acquiring an additional 3,942 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Xeris Pharmaceuticals in the 1st quarter worth $33,000. American International Group Inc. grew its holdings in Xeris Pharmaceuticals by 26.3% in the 1st quarter. American International Group Inc. now owns 21,090 shares of the company’s stock worth $41,000 after acquiring an additional 4,394 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in Xeris Pharmaceuticals by 26.7% in the 1st quarter. M&T Bank Corp now owns 26,036 shares of the company’s stock worth $51,000 after acquiring an additional 5,493 shares during the last quarter. 62.48% of the stock is currently owned by institutional investors and hedge funds.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.